Rocklatan® Evaluation

Key Inclusion Criteria:

• Male or female subjects age 18 or older
• Current diagnosis of open-angle glaucoma or ocular hypertension
• Subject currently being treated with latanoprost alone or latanoprost plus 1 or 2additional agents/bottles. Current IOP lowering regimen is stable for at least 30 daysprior to Baseline Visit
• Treated IOP ≥ 20 mmHg measured in the morning (before noon) at the Baseline Visit byGoldmann applanation tonometer
• Best corrected Snellen visual acuity of 20/100 or better in both eyes
• Willingness to follow protocol requirements, including signed informed consent andhealth information release forms, routine follow-up schedule, completingquestionnaires

Key Exclusion Criteria:

• Have any active ocular disease other than open-angle glaucoma or ocular hypertensionthat would interfere with study interpretation
• Use of fixed dose combination agents as part of the patient's Baseline IOP loweringtherapy regimen, if not also on latanoprost
• Active ocular infection/inflammation or history of uveitis
• Aphakic or pseudophakic patients with a torn posterior lens capsule, or with knownrisk factors for macular edema
• Any systemic disease or clinical evidence of any condition which would make thesubject, in the opinion of the investigator, unsuitable for the study or couldpotentially confound the study results
• Use of topical, periorbital, intravitreal or systemic steroid within previous 3 monthsor expected use during the course of the study
• Prior participation in any investigational drug or device study within the last 30days prior to the Baseline Visit.
• Known sensitivity or allergy to the study medication or components
• Females who are pregnant, nursing, or planning a pregnancy during the study
• Positive pregnancy test at Baseline Visit (women of childbearing potential only)
• Women of childbearing potential who are not using a medically acceptable form of birthcontrol